Natera, Inc. (NASDAQ:NTRA) CEO Sells $12,958,888.41 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48.
• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $468,111.60.

Natera Stock Up 2.7 %

Shares of Natera stock traded up $4.47 during trading hours on Wednesday, reaching $171.93. The company’s stock had a trading volume of 2,052,001 shares, compared to its average volume of 1,460,392. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock’s fifty day simple moving average is $165.35 and its two-hundred day simple moving average is $135.41. The company has a market capitalization of $22.70 billion, a P/E ratio of -97.69 and a beta of 1.65. Natera, Inc. has a one year low of $62.96 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. On average, research analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of Natera by 35.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock valued at $28,680,000 after purchasing an additional 69,523 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Natera in the second quarter valued at about $767,000. Amalgamated Bank grew its position in shares of Natera by 6.0% during the 2nd quarter. Amalgamated Bank now owns 7,590 shares of the medical research company’s stock valued at $822,000 after acquiring an additional 428 shares during the period. XTX Topco Ltd increased its stake in shares of Natera by 24.1% during the 2nd quarter. XTX Topco Ltd now owns 4,846 shares of the medical research company’s stock worth $525,000 after purchasing an additional 940 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of Natera by 4,082.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,821 shares of the medical research company’s stock worth $847,000 after purchasing an additional 7,634 shares during the period. 99.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on NTRA shares. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. TD Cowen boosted their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Canaccord Genuity Group upped their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $160.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.